Su1747 Fecal Microbiota Transplant Improves Symptoms in Patients with Pouchitis and Induces Changes in the Microbiome: Preliminary Results of an Open Label Trial

El-Nachef, Najwa; Lucey, Kaitlyn; Somsouk, Ma; Ma, Averil; Bethke, Mary; Leon, Kimberly; Lynch, Susan V.; Terdiman, Jonathan P.

doi:10.1016/s0016-5085(16)31864-9

Cited by 11 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A pilot RCT using FMT for the maintenance of remission in UC demonstrated improved endoscopic and histological outcomes over placebo without a significant difference in the primary endpoint of maintenance of steroid-free clinical remission 130. The role of FMT in Crohn’s disease17–22 and pouchitis131–135 is less clear with no published RCTs to date. The evidence supporting use of FMT in irritable bowel syndrome and other functional gut disorders is conflicting, despite several placebo-controlled trials, likely reflecting the heterogenous nature of irritable bowel syndrome and high placebo response rates 23–30.…”

Section: Resultsmentioning

confidence: 99%

Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice

Haifer

Kelly

Paramsothy

et al. 2020

Gut

View full text Add to dashboard Cite

ObjectiveFaecal microbiota transplantation (FMT) has proved to be an extremely effective treatment for recurrent Clostridioides difficile infection, and there is interest in its potential application in other gastrointestinal and systemic diseases. However, the recent death and episode of septicaemia following FMT highlights the need for further appraisal and guidelines on donor evaluation, production standards, treatment facilities and acceptable clinical indications.DesignFor these consensus statements, a 24-member multidisciplinary working group voted online and then convened in-person, using a modified Delphi approach to formulate and refine a series of recommendations based on best evidence and expert opinion. Invitations to participate were directed to Australian experts, with an international delegate assisting the development. The following issues regarding the use of FMT in clinical practice were addressed: donor selection and screening, clinical indications, requirements of FMT centres and future directions. Evidence was rated using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system.ResultsConsensus was reached on 27 statements to provide guidance on best practice in FMT. These include: (1) minimum standards for donor screening with recommended clinical selection criteria, blood and stool testing; (2) accepted routes of administration; (3) clinical indications; (4) minimum standards for FMT production and requirements for treatment facilities acknowledging distinction between single-site centres (eg, hospital-based) and stool banks; and (5) recommendations on future research and product development.ConclusionsThese FMT consensus statements provide comprehensive recommendations around the production and use of FMT in clinical practice with relevance to clinicians, researchers and policy makers.

show abstract

Section: Resultsmentioning

confidence: 99%

Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice

Haifer

Kelly

Paramsothy

et al. 2020

Gut

View full text Add to dashboard Cite

show abstract

“…After transplanting via pouchoscopy, there was a decrease in abdominal pain and number of bowel movements. No escalation of treatment was noted 70 . Fang et al was able to demonstrate an improvement of symptoms and quality of life for a patient with chronic antibiotic refractory pouchitis 71 .…”

Section: Fecal Microbiota Transplant In Pouchitismentioning

confidence: 99%

Update on Fecal Microbiota Transplantation In Inflammatory Bowel Diseases

Kwok¹,

Choi²,

Choi³

et al. 2018

BIOMEDJ

View full text Add to dashboard Cite

The microbiome in our digestive tract has beneficial and symbiotic effects on our health. Loss of this diversity may be associated with certain autoimmune diseases such as inflammatory bowel disease, a condition hallmarked by chronic inflammation of the gastrointestinal tract due to dysregulated immune response to host intestinal microflora. Fecal microbiota transplantation has been effective in treating medically refractory Clostridium difficile infection and is now being studied in other gastrointestinal diseases, including IBD. Several recent meta-analyses have been performed to determine the efficacy of using FMT in patients with Crohn's disease and Ulcerative Colitis. It has also been the focus of small trials in order to treat pouchitis and extraintestinal manifestations of IBD. This article is a systemic review of the up to date clinical trials and metaanalysis focusing on the use of FMT for patients with IBD.

show abstract

“…Only nine publications (seven articles and two abstract) describing two case reports and two open label studies, concerning a total of 62 patients, have been published on the subject of FMT in chronic pouchitis [31][32][33][34][35][36][37][38]. All of them produced heterogeneous results and these studies alone are clearly insufficient to promote this technique.…”

mentioning

confidence: 99%

Impact of fecal microbiota transplantation on chronic recurrent pouchitis in ulcerative colitis with ileo-anal anastomosis: study protocol for a prospective, multicenter, double-blind, randomized, controlled trial

Trang-Poisson

Kerdreux

Poinas

et al. 2020

Preprint

View full text Add to dashboard Cite

- Background: Almost 15 % of patients with ulcerative colitis (UC) will require a proctocolectomy with ileal pouch–anal anastomosis (IPAA) as a result of fulminant colitis, dysplasia, cancer, or medical refractory diseases. Around 50% will experience pouchitis, an idiopathic inflammatory condition involving the ileal reservoir, responsible for digestive symptoms, deterioration in quality of life, and disability. Though the majority of initial cases of pouchitis are easily managed with a short course of antibiotics, in about 10% of cases, inflammation of the pouch becomes chronic with very few treatments available. Previous studies have suggested that manipulating the composition of intestinal flora through antibiotics, probiotics, and prebiotics achieved significant results for treating acute episodes of UC-associated pouchitis. However, currently there is no established effective treatment for chronic antibiotic-dependent pouchitis. Fecal microbiota transplantation (FMT) is a novel therapy involving the transfer of normal intestinal flora from a healthy donor to a patient with a medical condition potentially caused by the disrupted homeostasis of intestinal microbiota or dysbiosis.-Methods Our project aims to compare the delay of relapse of chronic recurrent pouchitis after FMT versus sham transplantation. Forty-two patients with active recurrent pouchitis after having undergone an IPAA for UC will be enrolled at 12 French centers. The patients who respond to antibiotherapy will be randomized at a ratio of 1:1 to receive either FMT or sham transplantation.-Discussion : On April 30, 2014, WHO published an alarming report on antibiotic resistance. Finding an alternative medical treatment to antibiotics in order to prevent relapses of pouchitis is therefore becoming increasingly important given the risk posed by multiresistant bacteria. Moreover, if the results of this study are conclusive, FMT, which is less expensive than biologics, could become a routine treatment in the future.-Trial registration: The trial, published on May 14, 2018, is registered at ClinicalTrials.Gov under registration number NCT03524352: https://clinicaltrials.gov/ct2/show/NCT03524352term=NCT03524352&rank=1

show abstract

Su1747 Fecal Microbiota Transplant Improves Symptoms in Patients with Pouchitis and Induces Changes in the Microbiome: Preliminary Results of an Open Label Trial

Cited by 11 publications

References 0 publications

Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice

Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice

Update on Fecal Microbiota Transplantation In Inflammatory Bowel Diseases

Impact of fecal microbiota transplantation on chronic recurrent pouchitis in ulcerative colitis with ileo-anal anastomosis: study protocol for a prospective, multicenter, double-blind, randomized, controlled trial

Contact Info

Product

Resources

About